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(1 patient) and related death (1 patient). Non-haematologic 
grade 3/4 toxicities included fatigue, condition aggravated, 
hypokalaemia, tumour pain, acneiform dermatitis, diar-
rhoea, hyperbilirubinaemia and pulmonary haemorrhage, 
in one patient each. Of 25 patients evaluable for tumour 
response, 2 patients had partial response and 20 patients 
had stable disease.
Conclusion The recommended doses for oral vinflunine 
and erlotinib combination were, respectively, 115 mg/
day from day 1 to day 5 and from day 8 to day 12 every 
3 weeks and 150 mg/day. There was no mutual impact on 
pharmacokinetics. The combination was safe but evaluation 
in phase II is needed to further refine the activity and toxic-
ity that can be expected with prolonged administration of 
this dose schedule.
Keywords Erlotinib · Non-small-cell lung cancer ·  
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Introduction
Lung cancer is the most frequent neoplasm. Prognosis of 
patients with lung cancer is poor with relative 1-year sur-
vival rates approximately 30 % and 5-year rates around 
10 % [1]. Non-small-cell lung cancer (NSCLC) accounts 
for approximately 80–85 % of all primary lung neoplasm. 
Surgery is the preferred treatment of patients with early 
disease but more than 50–60 % of patients present with 
locally advanced (stage IIIB) or metastatic disease (stage 
IV) and they are not suitable for surgery. Systemic chemo-
therapy has demonstrated palliative benefit and modest pro-
longation of survival, and two-drug platinum-based chemo-
therapy is now the standard of care for good performance 
patients with unresectable locally advanced or metastatic 
Abstract 
Background Erlotinib, the epidermal growth factor 
receptor tyrosine kinase inhibitor, and the intra-venous 
vinflunine vinca alkaloid microtubule inhibitor have been 
shown to be effective in the setting of non-small-cell lung 
cancer (NSCLC) palliative patients with acceptable tox-
icities. This phase I study was conducted to determine the 
maximal tolerated dose (MTD) and the safety of an all-oral 
combination. A potential pharmacokinetic drug–drug inter-
action was also investigated.
Patients and methods Patients with unresectable stage 
IIIB or stage IV NSCLC who failed one or two previ-
ous chemotherapy regimens were treated with flat doses 
of oral vinflunine from day 1 to day 5 and from day 8 to 
day 12 every 3 weeks and erlotinib daily on a continuous 
basis. The dose levels of vinflunine/erlotinib were 95/100, 
115/100, 115/150 and 135/100 mg.
Results Thirty patients were enroled. The recommended 
dose was 115/150 mg and the MTD 135/100 mg. Dose-
limiting toxicities included grade 3 febrile neutropenia 
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disease [2, 3]. Second-line chemotherapy may be consid-
ered in patients with progression after initial platinum-
based regimen. Single-agent docetaxel and pemetrexed 
may produce life prolongation and symptomatic improve-
ment compared to best supportive care in some patients, 
both agents have been approved for use as second-line 
chemotherapy [4].
Recently, the epidermal growth factor receptor tyros-
ine kinase inhibitor (EGFR-TKI), erlotinib (Tarceva®) was 
investigated in NSCLC after the failure of first-line or sec-
ond-line chemotherapy. It prolonged survival, delayed dis-
ease progression and decreased symptoms, as compared to 
placebo in this clinical setting [5]. Vinflunine (VFL) admin-
istered intravenously in NSCLC patients previously treated 
with a platinum-containing regimen showed efficacy sim-
ilar to docetaxel [6]. In a randomized phase II study, the 
addition of chronic, intermittent, low-dose vinorelbine to 
the EGFR inhibitor gefitinib was effective and manage-
able in NSCLC patients who failed at least two regimens of 
chemotherapy. The addition of low-dose vinorelbine pro-
duced a significantly better 1-year progression-free survival 
rate (57.1 vs. 21.2 %; P = 0.008) [7]. Importantly, VFL is 
less neurotoxic than vinorelbine [8].
Given that VFL and erlotinib have an acceptable safety 
profile and have shown efficacy in second-line treatment 
of patients with advanced NSCLC, we hypothesized that 
the combination would result in acceptable toxicity and 
improved efficacy. Furthermore, they are both available as 
oral drugs. An all-oral combination regimen is an attrac-
tive option in the palliative setting of NSCLC patients. 
The goal of the present study was to determine the doses 
of oral VFL and erlotinib used safely in combination and 




Patients with histologically or cytologically confirmed 
NSCLC unresectable stage III B or stage IV disease or 
delayed relapse of any stage no longer amenable to sur-
gery or radiotherapy with curative intent were eligible. 
Other criteria included are as follows: age between 18 and 
75 years, Karnofsky performance status ≥70 % and life 
expectancy ≥3 months. Patients may have had one or two 
prior lines of chemotherapy regimen and they had to be at 
least 4 weeks since prior chemotherapy or 6 weeks if the 
last regimen included bleomycin or mitomycin C. Prior 
radiotherapy must have been completed at least 4 weeks 
before study entry. Adequate bone marrow (haemoglobin 
≥10 g/dL, absolute neutrophil count (ANC) >1.5 × 109/L, 
and platelet count >100 × 109/L), renal (serum creati-
nine < upper limit of normal (ULN) and creatinine clear-
ance ≥50 mL/min) and liver (total bilirubin ≤ ULN, 
AST and ALT ≤2.5 × ULN, and alkaline phosphatase 
≤5 × ULN, except in patients with documented bone or 
liver metastases) function were required. Patients of child-
bearing potential had to use a medically acceptable contra-
ception. Patients previously treated for central nervous sys-
tem metastases were eligible if they were stable by CT scan 
or MRI without evidence of cerebral oedema and had no 
requirement for steroids or anticonvulsivants. Patients with 
pre-existing grade ≥2 peripheral neuropathy or dysphagia 
according to the National Cancer Institute (NCI) Com-
mon Toxicity Criteria (CTC) version 3.0 were not eligible. 
Patients previously treated with VFL and/or EGFR inhibi-
tor were not eligible. Finally, patients with any underlying 
medical condition likely to be aggravated by study treat-
ment and patients receiving a concomitant therapy with 
strong inhibitors or inducers of the cytochrome P450 iso-
form 3A4 were not eligible. The protocol, patient informa-
tion and written informed consent were submitted to Inde-
pendent Ethics Committees according to the participating 
countries requirement. All patients had to give written per-
sonally signed informed consent.
Criteria for evaluation
Dose-limiting toxicities (DLT) were defined as the occur-
rence during the first cycle of one of the following: 
ANC <0.5 × 109/L for ≥7 days, grade 3 or 4 neutropenia 
concomitant with fever ≥38.5 °C or grade ≥3 infection, 
platelet count <25 × 109/L or <50 × 109/L with bleeding, 
grade ≥3 nausea, vomiting or diarrhoea if persistent despite 
optimal antiemetic or antidiarrhoeal treatment, grade 3 
intestinal ileus, any other drug-related grade ≥3 toxic-
ity and any other drug-related adverse event that results in 
30 % dosing omission during cycle 1 or a delay ≥2 weeks 
in the administration of cycle 2.
Maximal tolerated dose (MTD) was defined as the high-
est dose at which 2 out of 3 or 2 out of 6 patients devel-
oped a DLT during the first cycle. The recommended dose 
(RD) was the dose below the MTD. It was confirmed by 
accrual of at least 10 new patients up to a total of at least 16 
patients at the end of the phase I.
Efficacy was assessed by using RECIST criteria (version 
1.0). Tumour assessments were performed at baseline, at 
the end of cycle 2 and then every 2 cycles.
Safety was assessed by physical examination and labo-
ratory tests twice weekly during cycle 1, then weekly in 
the following cycle. Toxicity was graded according to the 
NCI–CTC version 3.0.
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Study design and treatment plan
This was an open-label, European multicentre, dose-escala-
tion phase I study. Primary objective was to determine the 
MTD of oral VFL administered once a day from day 1 to 
day 5 and from day 8 to day 12 every 3 weeks in combina-
tion with erlotinib given once a day on a continuous basis. 
Secondary objectives were to assess the safety of the com-
bination, to investigate a potential pharmacokinetic drug–
drug interaction and to assess antitumour activity in NSCLC 
patients. The doses of VFL and erlotinib were escalated in 
cohorts of 3–6 patients. A cycle was defined as a 3-week 
period. Each patient had to receive at least one cycle of the 
combination to be evaluable for MTD determination and 
two cycles to be evaluable for pharmacokinetics (PK). The 
dose-escalation scheme is summarized in Table 1.
Patients received at least 2 cycles of treatment unless 
unacceptable toxicity, patient’s refusal or disease progres-
sion. Patients with response or stable disease after 6 cycles 
were allowed to continue their treatment at the discretion of 
the investigator and underwent the same monitoring as dur-
ing the first 6 cycles.
Pharmacokinetic
Pharmacokinetics (PK) of VFL and erlotinib involve mech-
anisms that are common between both agents: absorption 
through the alimentary tract wall after oral administration 
and important metabolization by CYP3A4.
In order to evaluate the potential drug–drug interac-
tion, the PK of both drugs had to be assessed alone and in 
combination. To obtain a PK profile of VFL alone, the first 
administration of erlotinib in Cycle 1 was delayed on Day 
2. Day 1 of Cycle 1 was the VFL.
The effect of erlotinib on the VFL PK was assessed at its 
steady state. Day 1 of Cycle 2 was the test period.
The reference for the PK of erlotinib was on day 21 
when VFL concentrations were at their minimum. Poten-
tial effect of VFL on the PK of erlotinib could be expected 
when concentrations of VFL were at its maximal (D12) and 
at the steady state of erlotinib (starting on D8). Therefore, 
PK of erlotinib co-administered with VFL was evaluated on 
day 12 (Test period).
Pharmacokinetics (PK) of VFL was studied by meas-
uring whole blood concentrations using a fully validated 
LC–MS/MS method with a lower limit of quantification of 
0.25 ng/mL [9]. Erlotinib and its metabolite OSI-420 were 
quantified in plasma using a fully validated LC–MS/MS 
method with a LLOQ of 1 ng/mL [10].
Pharmacokinetic parameters (AUC0−24h) of VFL, erlo-
tinib and OSI-420 were estimated using non-compartmen-
tal calculation methods.
The effect of concomitant administration of one drug on 
the PK of the other was assessed by building the 90 % CI for 
the test/reference ratio of geometric means of AUC0−24h/dose.
Results
Patient baseline characteristics
A total of 30 patients with locally advanced or metastatic 
NSCLC were enroled in the study between December 2008 
Table 1  Dose-escalation schema








Table 2  Patient baseline characteristics
* Data missing for one patient
Number of patients 30
Median age, years (range) 58.1 (47.0–71.1)
Gender M/F 18/12
Performance status
 70 1 (3.3 %)
 80 3 (10.0 %)
 90 14 (46.7 %)
 100 12 (40.0 %)
Histopathological type
 Adenocarcinoma 11 (36.7 %)
 Large cell carcinoma 9 (30.0 %)
 Other 8 (26.7 %)
Stage at diagnosis
 IIB 2 (6.7 %)
 IIIA 3 (10.0 %)
 IIIB 10 (33.3 %)
 IV 15 (50.0 %)
Extent of disease
 1 organ 12 (40.0 %)
 2 organs 12 (40.0 %)
 =3 organs 6 (20.0 %)
Disease-free interval (years*)
 <2 years 26 (89.7 %)
 =2 years 3 (10.3 %)
Prior chemotherapy
 Neoadjuvant 3 (10.0 %)
 Adjuvant 5 (16.7 %)
 Advanced 25 (83.3 %)
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and April 2010. Patient baseline characteristics are summa-
rized in Table 2. Twenty-five patients (83.3 %) had received 
at least one chemotherapy line in the locally advanced/
metastatic setting. Out of the 30 patients enroled, 5 patients 
were pre-treated with vinca alkaloids (vinorelbine), 2 in the 
neoadjuvant setting and 3 in the advanced disease setting. 
The majority of the patients had a performance status of 
90–100 % (86.7 %).
Determination of the MTD and RD
No DLT was reported in the first dose level (95 mg/day 
VFL + 100 mg/day erlotinib). At the second dose level 
(115–100), one patient out of the first 3 included experi-
enced a DLT (grade 3 febrile neutropenia). Three addi-
tional patients included at this dose level did not expe-
rience any DLT. Dose was further escalated to level 3 
(115–150), at which no DLT was observed among the 
first 3 included patients. Therefore, dose escalation was 
pursued to level 4 (135–100): 2 of the 3 included patients 
experienced a DLT corresponding to the definition of the 
MTD (grade 3 febrile neutropenia concomitant with grade 
2 asthenia, and death which was considered drug-related). 
Additional patients were included at dose level 3 (115–
150) in order to confirm the RD. Among the 15 newly 
included patients for a total of 18, 4 patients (22.2 %) 
experienced a DLT (grade 4 neutropenia and grade 4 diar-
rhoea; grade 4 pulmonary haemorrhage; grade 4 neutrope-
nia and grade 3 rash acneiform.
Safety
Haematological toxicity was the most frequent and was 
per patient: anaemia (96.7 %), neutropenia (36.7 %) and 
thrombocytopenia (16.7 %). Of note 12 patients (40.0 %) 
had already grade ≥1 anaemia at baseline. Five patients 
received blood transfusions during the study. Only 2 
patients (6.7 %) experienced febrile neutropenia (at 115–
100 and 135–100 mg/day), and one patient experienced 
neutropenic infection at 115–100 mg/day.
Grade 3 drug-related events per patient included are as 
follows: anaemia (20.0 %), neutropenia (16.7 %), fatigue 
(10.0 %), febrile neutropenia (6.7 %), thrombocytopenia, 
condition aggravated, hypokalaemia, tumour pain and der-
matitis acneiform (3.3 %). Grade 4-related events were lim-
ited to neutropenia (23.3 %), diarrhoea, hyperbilirubinae-
mia and pulmonary haemorrhage (3.3 %).
At the RD, among the 18 treated patients, grade 3 events 
observed were neutropenia in 4 patients, anaemia in 3 
patients and thrombocytopenia in 1 patient.
Grade 4 was reported only for neutropenia in 3 patients. 
Grade 3 drug-related non-haematological events were lim-
ited to fatigue, hypokalaemia and dermatitis acneiform in 
one patient each, and grade 4 events were observed for 
diarrhoea, hyperbilirubinaemia and pulmonary haemor-
rhage in one patient each.
Five (16.7 %) patients died during study treatment, and 
for 2 of them (6.7 %), the relationship to study drug was 
suspected (disseminated intravascular coagulation and pul-
monary haemorrhage).
Drug-related grade 3 or 4 toxicities are summarized 
according to the dose levels in Table 3.
Efficacy
Partial response was observed and confirmed in two 
patients (6.7 %), one at dose level 1 (33.3 %) and one 
(5.6 %) at dose level 3. Stable disease was achieved in 20 
patients (80 %) among 25 patients evaluable for tumour 
response: 2 (66.7 %) at dose level 1, 4 (66.7 %) at dose 
level 2, 13 (72.2 %) at dose level 3 and 1 (33.3 %) at dose 
level 4.
Table 3  Grade 3/4 drug-related toxicities observed in all cycles
Grade ¾ toxicity Level 1 (n = 3) Level 2 (n = 6) Level 3 (n = 18) Level 4 (n = 3) All (n = 30)
Anaemia – 3 (50 %) 3 (16.7 %) – 6 (20.0 %)
Neutropenia 1 (33.3 %) 2 (33.3 %) 7 (38.9 %) 2 (66.7 %) 12 (40.0 %)
Thrombocytopenia – – 1 (5.6 %) – 1 (3.3 %)
Febrile neutropenia – 1 (16.7 %) – 1 (33.3 %) 2 (6.7 %)
Diarrhoea – – 1 (5.6 %) – 1 (3.3 %)
Condition aggravated – 1 (16.7 %) – – 1 (3.3 %)
Fatigue – 2 (33.3 %) 1 (5.6 %) – 3 (10.0 %)
Hyperbilirubinaemia – – 1 (5.6 %) – 1 (3.3 %)
Hypokalaemia – – 1 (5.6 %) – 1 (3.3 %)
Tumour pain – – – 1 (33.3 %) 1 (33.3 %)
Pulmonary haemorrhage – – 1 (5.6 %) – 1 (3.3 %)
Dermatitis acneiform – – 1 (5.6 %) – 1 (3.3 %)
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Pharmacokinetic results
For VFL pharmacokinetic assessment, 25 patients and 19 
patients were fully evaluable on day 1 of cycle 1 and on 
day 1 of cycle 2, respectively. Only 15 patients were evalu-
able on both days. Mean value of AUC0−24h at the RD of 
115 mg for VFL/150 mg for ERL was 643 h.ng/mL on day 
1 of cycle 1 (n = 17, range [266–1,474]) and 720 h.ng/mL 
on day 1 of cycle 2 (n = 12, range [326–1,831]).
The test/reference ratio of geometric mean of AUC0−24h/
dose, calculated on 15 patients (all dose level pooled), was 
1.22. The CI 90 % was [1.03–1.43]. When including all avail-
able individual PK parameters, the comparison of AUC0−24h 
normalized by the dose level showed no difference between 
day 1 and day 22 with similar mean values (Fig. 1).
For erlotinib PK assessment, 23 patients were evaluable 
on day 12, 18, on day 21 and 18 on both days. Mean value 
of AUC0−24h at the RD was 3,201 h.ng/mL on day 12 of 
cycle 1 (n = 15, range [649–8,542]) and 2,996 h.ng/mL on 
day 21 of cycle 1 (n = 10, range [987–11,404]).
The statistical analysis was performed on 18 patients (all 
dose level pooled) on AUC/dose of erlotinib. The test/ref-
erence ratio was 1.17. The 90 % CI was [1.05–1.31]. The 
metabolic ratio of OSI-420 formed through CYP3A4 meta-
bolic pathway, was stable between day 12 and day 21 (point 
estimates of 1.00 with 90 % CI of 0.95–1.05) (Fig. 2).
Discussion
We report the results of a phase I dose-finding study of 
VFL orally administered once daily from day 1 to day 5 
and from day 8 to day 12 every 3 weeks in combination 
with erlotinib given orally once daily on a continuous basis 
in patients with locally advanced or metastatic NSCLC. 
The RD was defined at 115–150 mg, dose at which 5.6 % 
of patients achieved a partial response and 72.2 % experi-
enced stable disease.
Oral chemotherapy is considered to be more conveni-
ent for patients than intravenous treatment and offers the 
added advantages of a chronic schedule without the need of 
intravenous devices. Its potential for enhancing anti-tumour 
effect and improving patient quality of life is of special 
interest in the palliative setting of metastatic disease.
However, this combination increases the risk of hae-
matologic toxicity compared to either agent alone. Forty 
per cent of patients (38.9 % at the RD) experienced grade 
3/4 neutropenia. Neutropenia was the main cause limit-
ing delivery of treatment and requiring dose delays. These 
results are similar to those reported by Davies et al. [11] 
in a phase I study of erlotinib and vinorelbine in advanced 
malignant solid tumours and by Scagliotti et al. [12] when 
combining gefitinib with vinorelbine in a phase II study. 
Nevertheless, it can be noticed that neutropenia did not 
translate to a high incidence of severe toxicities, as only 2 
patients experienced febrile neutropenia, and one patient 
experienced neutropenic infection. None of the 18 patients 
at RD experienced complicated neutropenia.
Both agents are metabolized through cytochrome 3A4, 
and therefore, potential drug–drug interaction was evalu-
ated in this study. Given higher PK variability with oral 
drugs and the limited number of patients included into 
statistical analysis, sufficient power could not be reached 
to conclude with an acceptance interval of [0.8–1.25]. 
Day 1 without ERL 
n=25














Fig. 1  Comparison of VFL AUC0−24h normalized by the dose 
between days of treatment in all patients included in the study
 Day 12 with VFL
 n= 23



















Fig. 2  Comparison of OSI-420 metabolic ratio between days of 
treatment in all patients included in the study
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However, confidence intervals are included in a widened 
range of [0.7–1.43] commonly used for more variable 
drugs.
Indeed, the graphical comparison of VFL AUC0−24h 
normalized by the dose level using data from all patients 
showed overlapping range of values and no consistent trend 
of individual values between VFL monotherapy and co-
administration with erlotinib.
For erlotinib PK assessment, a drug–drug interaction 
between both agents would be driven by the inhibition 
of CYP3A4, and this inhibition would have induced a 
decrease in the formation of OSI-420 from ERL and as a 
consequence a decrease in the metabolic ratio of OSI-420 
over ERL. However, the confidence interval of this meta-
bolic ratio is fully included in the acceptance range with a 
test/reference ratio of 1, showing a lack of VFL impact on 
its formation.
Therefore, a lack of mutual impact on PK when VFL 
and erlotinib were co-administered can be concluded.
This phase I study shows that oral VFL and erlotinib 
combination can be delivered safely with acceptable tox-
icity in unselected patients with locally advanced or meta-
static NSCLC. However, more toxicity evaluation in phase 
II is needed to further refine the real toxicity that can be 
expected with prolonged administration with this dose 
schedule.
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